Posts

IVX Health, National Provider Of Outpatient Infusion Centers, Secures $100 Million Growth Investment To Accelerate New Market Expansion

/in , , /by

IVX Health, a national provider of outpatient infusion centers, announcedt the completion of a $100 million Series F minority investment from Great Hill Partners, a private equity firm that invests in high-growth, disruptive companies.

Great Hill joins IVX Health’s existing investors including Linden Structured Capital, McKesson Ventures, Health Velocity Capital, and Nueterra Capital.

IVX Health offers an alternative to hospital-based infusion and injection services, transforming the patient experience by providing a superior level of service in a cost-effective, convenient site of care. Its local centers offer guaranteed private suites, large flat screen TVs, high-speed Wi-Fi, leather recliners with chairs for guests, and flexible, on-demand scheduling, including evening and weekend appointments.

Operating over 50 infusion centers across 16 markets, IVX Health will immediately utilize the funding to accelerate entry into new markets in 2022 and beyond as it seeks to fulfill its vision of becoming the nation’s preferred destination of pharmaceutical care for patients with complex chronic conditions such as multiple sclerosis, Crohn’s disease, and rheumatoid arthritis, among others.

“Our primary goal has always been to provide world-class service and clinical excellence to the patients we serve,” said Doug Ghertner, CEO of IVX Health. “IVX and Great Hill both see an inflection point in infusion therapy, as the growth in diagnosed autoimmune conditions and trends toward patient choice have aligned with an uptick in innovative new therapies. Many patients are unfortunately still left with few options for receiving this life-changing care, often within a crowded infusion room of a hospital – and that’s where we come in. We are confident that Great Hill’s investment and deep domain expertise will help us address this shortage of care options by enabling IVX to bring our unique clinical model and patient-centered amenities to an even broader universe of patients.”

“IVX Health is disrupting a distinct and rapidly growing healthcare vertical – biologic infusion and injection therapy – in unique ways that are driving tangible efficiencies for the U.S. healthcare system as a whole,” said Mark Taber, a Managing Director at Great Hill Partners. “We are excited to play a strategic, supporting role in fueling IVX Health’s next phase of growth as it enters new markets and collaborates with other providers in the healthcare ecosystem to drive value while continuing to redefine the care experience for its patients and referring providers.”

In connection with the investment, Taber will join IVX Health’s Board of Directors. Taber brings decades of executive healthcare experience from his time as Managing Director at Great Hill and as a board member of various portfolio companies.

In addition to IVX Health, Great Hill’s portfolio of healthcare companies includes: RxBenefits, Quantum Health, Labor First, ParetoHealth, and Vatica Health. The announcement deepens Great Hill’s experience partnering with innovative healthcare companies to help them pursue their full potential, which includes the recently-sold company, PartsSource, a leading provider of medical parts and supplies procurement solutions for hospitals, outpatient clinics, and physician offices.

IVX Health’s capital raise builds on what has already been a banner year for the company, as it has achieved record milestones for opening new centers, caring for new patients, and entering new states. IVX Health was also named to the prestigious Modern Healthcare Best Places to Work list for a third consecutive year. The organization continues to maintain an industry-leading 97 Net Promoter Score from its patient population.

Evercore served as financial advisor to IVX Health and TripleTree, LLC served as financial advisor to Great Hill.

About IVX Health

IVX Health is a national provider of infusion and injection therapy for those with complex chronic conditions such as rheumatoid arthritis, Crohn’s disease, multiple sclerosis and other conditions.

IVX Health’s national footprint of outpatient infusion centers are conveniently located in the communities where patients live and work. IVX Health’s experience-first model includes amenities such as flexible appointment scheduling with evening and weekend availability, guaranteed private suites, high-speed Wi-Fi, flat screen TVs with streaming TV and movies, and comfortable recliners with room for guests. For more information on IVX Health and its existing locations, visit www.ivxhealth.com.

About Great Hill Partners

Great Hill Partners is a Boston-based private equity firm targeting investments of $25 million to $500 million in high-growth companies across the software, digital commerce, financial technology, healthcare, and digital infrastructure sectors. Over the past two decades, Great Hill has raised nearly $8 billion of commitments and invested in more than 75 companies, establishing an extensive track record of building long-term partnerships with entrepreneurs and providing flexible resources to help middle-market companies scale. For more information, including a list of all Great Hill investments, visit www.greathillpartners.com.

 

Source: businesswire

Allianz Lends $234M For MOB Portfolio Acquisition

/in , /by

In a $620.4 million deal, Nuveen Real Estate and NexCore have acquired a coast-to-coast portfolio of health-care and life science properties encompassing nearly 1.2 million square feet. The seller was IRA Capital.

The majority of the portfolio is a diversified group of 27 health-care assets that traded for $463 million. The portfolio encompasses properties in multiple states: Arizona, California, Florida, Illinois, Michigan, North Carolina, New Jersey, New York, Pennsylvania, Texas and Wisconsin.

Totaling nearly 750,000 square feet, the properties range from medical office buildings, micro-hospitals and ambulatory surgery facilities to cancer treatment centers. NexCore Group joined Nuveen Real Estate in underwriting the deal and will manage the assets.

The health-care portion of the transaction was led by Nuveen Real Estate’s new U.S. Cities Office Fund and brings the value of the firm’s holdings in the sector to more than $1 billion. Andrew Pike, head of health-care, cited the firm’s plans for aggressive growth in the sector.

Allianz Real Estate provided a $234 million loan toward the medical office acquisition. The loan will provide 51 percent of the total acquisition price, and the sponsors will have $228.9 million of equity in the transaction. The deal is structured on a seven-year term with a fixed-rate tranche of $163.8 million (70 percent) and a floating-rate tranche of $70.2 million (30 percent).

The portfolio is 99 percent occupied by 38 tenants, of which 92 percent are investment-grade credit healthcare systems. The portfolio rent roll has a weighted average unexpired lease term of 12 years, providing for a reasonable lease rollover profile during the loan term, according to Allianz.

Twenty of the 27 properties are in Certificate of Need (CON) states, where local governments require an extensive approval process to demonstrate a need for new healthcare facilities, providing high barriers to entry and regulatory restrictions around new supply.

Medical Sector Recovers

In a prepared statement, Mike Cale, co-head of U.S. Debt, Allianz Real Estate, U.S., said:  “The pandemic has emphasized the need for improved access to health-care. That trend has been illustrated by the demand for both outpatient facilities and hospital space for acute care. The medical office sector represents a unique, resilient asset class.”

This transaction marks Allianz’s second U.S. debt deal with Nuveen Real Estate, following Allianz’s $94 million financing of a six-property industrial portfolio for Nuveen’s U.S. Cities Industrial Fund in 2020.

The lack of demand for routine care and limitations on elective procedures, both in response to the COVID-19 pandemic, contributed to a 6.4 percent loss in health care employment in 2020, according to an April report from CBRE. That loss, however, was much less than in the overall economy, and health care jobs are rebounding rapidly.

Medical office buildings showed similar resilience, with annual investment volume falling by just 12.7 percent, the smallest decline for any major product category. Meanwhile, medical office property sales volume jumped in the fourth quarter of 2020, as cap rates continued a decade-long decrease.

Also part of the deal is the $157 million acquisition of two life science properties in Madison, Wis., and Orange County, Calif. Fully leased to three tenants, the assets comprise 420,000 square feet and will add to Nuveen’s 4 million-square-foot life science portfolio. The properties were acquired via TIAA’s balance sheet, according to Nuveen Real Estate.

Since November 2020, Nuveen and NexCore have teamed up on transactions valued at $687 million, noted Todd Varney, NexCore’s chief development officer & managing partner. The assets include 34 buildings totaling 1.4 million square feet, along with 200,000 square feet in development.

 

Source: Commercial Property Executive

Myconic Capital Enters Into Letter Of Intent To Acquire Interest In Miami-Based Tristar Wellness And Develop Satellite Ketamine Micro-Clinics

/in , /by

Myconic Capital Corp. (formerly, Auralite Investments Inc.) has entered into a letter of intent with Tristar Wellness LLC, operator of a wellness clinic in the Miami Beach area.

Pursuant to the terms of the letter of intent, it is contemplated that the company would acquire 49% of all issued and outstanding shares of Tristar. Tristar is an established clinic offering a broad scope of wellness-related treatments, including: primary care; pain management; addiction medicine; and various intravenous (IV) therapies (e.g., immune system and energy boosts).

Tristar introduced ketamine infusions to its offerings in response to increasing popularity of this approach to treating conditions such as depression, general anxiety disorder, and post-traumatic stress disorder. This planned acquisition adds a new geographic focus and complements other strategic acquisitions of clinic operators presently being pursued by Myconic, including Mindscape Ketamine & Infusions Therapy, PLLC of Houston, Texas (as announced in a March 10, 2021 press release); and NY Ketamine Medical Practice, PLLC of New York City (as announced in an April 5, 2021 press release).

In addition to the proposed acquisition of 49% of Tristar and its existing wellness clinic in Miami Beach, Florida, Myconic has agreed to finance the development of a portfolio of satellite ketamine micro-clinics in South Florida by advancing 100% of all construction and early-stage operation costs in exchange for a 50% interest in each micro-clinic. The development of the micro-clinics is subject to the formation of a joint venture entity and pending all required state, municipal and regulatory approvals.

Transaction Highlights

• The transaction leverages Myconic’s growing investment presence in ketamine infusion therapies in the United States, alongside current transactions of other micro-clinics offering these services in Texas and New York.

• Reliable source of recurring cash with Tristar’s Miami Beach clinic generating more than US$800,000 in revenue in 2020.

• Intrinsic scalability of service offering and micro-clinic portfolio in the state of Florida.

Pursuant to the LOI, Myconic would acquire 49% of the issued and outstanding shares of Tristar for a net purchase price of USD $818,300, comprised of: (i) US$523,300 equivalent value in common shares in the capital of Myconic, (ii) US$245,000 in cash to reduce existing debt obligations, and (iii) US$50,000 working capital to be applied to search engine optimization and marketing purposes.

The payment shares will be subject to a lockup period of 24 months on issuance, with 15% of the payment shares released 4 months and 1 day following closing, 40% of the payment shares released 12 months following closing and 45% of the payment shares released 24 months following the closing of the acquisition as contemplated in the LOI.

Robert Meister, CEO noted, “Purchasing an equity stake in Tristar is an exciting opportunity for us to strengthen our initiatives to become a key player amongst the leaders in the ketamine infusion space. Miami Beach is an important US market for wellness and innovative healthcare, both for area residents and as a destination for medical tourism. This transaction allows us to enter a key market, with the opportunity to grow in Florida with future facilities. We look forward to working with Tristar’s team to create value together in the operation of their existing clinics, and work towards scaling Tristar’s total reach through the planning and developing of new micro-clinic facilities.”

The completion of the acquisition is subject to a number of conditions which include but are not limited to the execution of a definitive agreement, completion of satisfactory due diligence of Tristar, and the approval of the transaction by the boards of directors of each of Myconic and Tristar.

About Tristar

More information about Tristar can be found on its website: https://www.tristarwell.com/

About Myconic

Myconic Capital Corp is an investment issuer with a diversified portfolio that is focused on emerging companies active in the high-tech, real estate, cannabis, mining and health & wellness sectors.

 

Source: StreetInsider